Effect of ibuprofen and acetylsalicylic acid on cognitive decline, total antioxidant power and serum isoprostanes;Efecto del ibuprofeno y ácido acetilsalicílico sobre el deterioro cognitivo, poder antioxidante total e isoprostanos séricos

Gaceta Medica de Mexico

Volumn 144, Issue 6, 2008, Pages 497-502

  Ibáñez Hernández, Marcia Gabriela ^a   Macías Islas, Miguel Ángel ^a   Zavalza Gómez, Ana Bertha ^b   Pacheco Moisés, Fermín Paul ^c   Ortiz, Genaro Gabriel ^c  

^a HOSPITAL DE ESPECIALIDADES   (Mexico)

^b INSTITUTO MEXICANO DEL SEGURO SOCIAL   (Mexico)

^c UNIVERSITY OF GUADALAJARA   (Mexico)

Author keywords

Acetylsalicylic acid; Cognitive impairment; Ibuprofen; Isoprostane; Serum total antioxidant power

Indexed keywords

ACETYLSALICYLIC ACID; ANTIOXIDANT; IBUPROFEN; ISOPROSTANE DERIVATIVE; NONSTEROID ANTIINFLAMMATORY AGENT;

ARTICLE; BLOOD; CLINICAL TRIAL; COGNITION; COGNITIVE DEFECT; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; FEMALE; HUMAN; MIDDLE AGED; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIOXIDANTS; ASPIRIN; COGNITION; COGNITION DISORDERS; FEMALE; HUMANS; IBUPROFEN; ISOPROSTANES; MIDDLE AGED; SINGLE-BLIND METHOD;

EID: 61549092177     PISSN: 00163813     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Ardila A. El proceso de envejecimiento normal. En: Arango JC, Fernández S, Ardila A, editores. Las demencias. Aspectos clínicos, neuropsicológicos y tratamiento. México: El Manual Moderno; 2003. pp. 3-7.
2. Small GW. What we need to know about age related memory loss. BMJ 2002;324:1502-1505.
3. Kryscio RJ, Schmitt FA, Salazar JC. Risk factors for transitions from normal to mild cognitive impairment and dementia. Neurology 2006;66:828-832.
4. Greenaway MC, Lacritz LH, Binegar D. Patterns of verbal memory performance in mild cognitive impairment, Alzheimer disease, and normal aging. Cog Behav Neurol 2006;19:79-84.
5. Grundman M, Petersen RC, Ferris SH. Mild cognitive impairment can be distinguished from Alzheimer disease and normal aging for clinical trials. Arch Neurol 2004;61:59-66.
6. Fernández S. Evaluación neuropsicológica de las demencias. En: Arango JC, Fernández S, Ardila A, editores. Las demencias. Aspectos clínicos, neuropsicológicos y tratamiento. México: El Manual Moderno; 2003. p. 143.
7. Mohr E. Diseño de ensayos clínicos en la época de los tratamientos de la demencia: dificultades y opciones. En: Gauthier S, Scheltens P, Cummings JL, editores. Enfermedad de Alzheimer y trastornos relacionados. Barcelona, España: Ars Medica; 2006. pp. 119-120.
8. Folstein MF, Folstein SE, McHugh PR. Minimental state: A practical guide for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975; 12:189-198.
9. Ostrosky F. Determination of normative criteria and validation of the SKT for its use in spanish population. J Int Psychogeriatr 1999:2-11.
10. Aguado C. Adaptación y validación al castellano de la versión abreviada de la Geriatric Depresión Scale (GDS) de Yesavage. Aten Primaria 2000; 26(Supl 1):328.
11. Nunomura A, Castellani RJ, Zhu X. Involvement of oxidative stress in Alzheimer disease. J Neuropathol Exp Neurol 2006;65(7):631-641.
12. Head E, Liu J, Hagen M. Oxidative damage increases with age in a canine model of human brain aging. J Neurochem 2002;82:375-381.
13. Dorado C, Rugeiro C, Rivas S. Estrés oxidativo y neurodegeneración. Rev Fac Med UNAM 2003;46(6):229-235.
14. 2-isoprostane concentration in probable AD. Neurology 1999;52(3):562-565.
15. Mark RJ, Fuson KS, May PC. Characterization of 8-epiprostaglandin FF2(alpha) as a marker of amyloid [beta]-peptide-induced oxidative damage. J Neurochem 1999;72(3):1146-1153.
16. Veld BA, Ruitenberg A, Hofman A. Nonsteroidal antiinflammatory drugs and the risk of Alzheimer's disease. N Engl J Med 2001;345:1515-1521.
17. Broe GA, Grayson DA, Creasey HM. Anti-inflammatory drugs protect against Alzheimer disease at low doses. Arch Neurol 2000;57:1586-1591.
18. Kang JH, Grodstein F. Regular use of nonsteroidal anti-inflammatory drugs and cognitive function in aging women. Neurology 2003;60:1591-1597.
19. Crean AJ, Gussekloo J, Vrijsen B. Meta-analysis of nonsteroidal antiinflammatory drug use and risk of dementia. Am J Epidemiol 2005;161:114-120.
20. Jantzen PT, Connor KE, DiCarlo G. Microglial activation and-amyloid deposits reduction caused by nitric oxide-releasing nonsteroidal anti-inflammatory drug in amyloid precursor protein plus presenilin-1 transgenic mice. J Neurosci 2002;(6):2246-2254.
21. McGeer PL, Schuzer M, McGeer EG. Arthritis and anti-inflammatory agents as possible protective factors for Alzheimer's disease: A review of 17 epidemiologic studies. Neurology 1996;47(2):425-432.
22. Reines SA. Block GA, Morris JC. Rofecoxib No effect on Alzheimer's disease in a 1-year, randomized, blinded, controlled study. Neurology 2004;62:66-71.
23. Halliday GM, Shepherd CE, McCann HD. Effect of anti-inflammatory medications on neuropathological findings in Alzheimer disease. Arch Neurol 2000; 57(6):831-836.
24. Eriksen JL, Sagi SA, Smith TE. NSAIDs and enatiomers of flurbiprofen target N-secretase and lower A-42 in vivo. J Clin Invest 2003;112:440-449.
25. Sugaya K, Uz T, Kumar V. New anti-inflammatory treatment strategy in Alzheimer's disease. Jpn J Pharmacol 2000;82:85-94.
26. Bradbury J. New mechanism proposed for NSAIDs reduction of Alzheimer's disease incidence. Lancet 2001;358:1616.
27. Broe GA, Grayson DA, Creasey HM. Anti-inflammatory drugs protect against Alzheimer disease at low doses. Arch Neurol 2000;57(11):1586-1591.
28. Etminan M, Gill S, Samii A. Effect of non-steroidal anti-inflammatory drugs on risk of Alzheimer's disease: systematic review and meta-analysis of observational studies. BMJ 2003;327:128-131.
29. Oxford Biomedical Research. Enzyme immunoassay for isoprostane. Product No. EA 84.
30. Oxford Biomedical Research. Colorimetric microplate assay for total antioxidant power. Product No. TA 01.
31. Cockrell JR, Folstein MF. Minimental state examination (MMSE). Psychopharmacol Bull 1988;24:689-692.
32. Lim GP, Yang F, Chu T. Ibuprofen suppresses plaque pathology and inflammation in a mouse model for Alzheimer's disease. J Neurosci 2000;20(15):5709-5714.
33. Sung JJY, Russell RI, Yeomans N, Chan FKL, Chen SL, Fock KM. Nonsteroidal anti-inflammatory drug toxicity in the upper gastrointestinal tract. J Gastroenterol Hepatol 2000;(Suppl):G58-G68.
34. Aalami OO, Fang TD, Song HM, Nacamuli RP. Physiological features of aging persons. Arch Surg 2003;(138):1068-1076.
35. Russell RI. Non-steroidal anti-inflammatory drugs and gastrointestinal damage-problems and solutions. Postgraduate Med J 2001;77(904):82-88.
36. Huerta C, Varas-Lorenzo C, Castellsague J, Rodríguez LA. Non-steroidal anti-inflammatory drugs and risk of first hospital admission for heart failure in the general population. Heart 2006;92(11):1610-1615.
37. th edition. Republic of Singapure: Maxwell Macmillan International Editions; 1991. pp. 638-681.